Nuvama lists out 4 reasons why they have rated MphasiS Buy. However they have a revised the price target lower. Find out why?

Investor concerns over the renewable energy sector's near-term prospects were evident on Friday, with Adani Green Energy ...

Nuvama Wealth Management announced the date to declare its third-quarter FY2024-25 results on Friday, January 24. Shares were ...

The brokerage firm, Nuvama, has raised its target price for UltraTech Cement to Rs 11,574 per share while maintaining its ...

Spandana Sphoorty shares hit lower circuit after it reported a net loss of ₹394 crore for the quarter ended December 2024 as ...

The generic drugmaker was the top loser on the Nifty Pharma index and the benchmark Nifty 50 index. "The drop in shares comes ...

NewsVoir Mumbai Maharashtra [India] January 24 The modern workplace continues to evolve beyond aesthetics and UrbanWrk a ...

Cyient's profit fell 31.7 per cent quarter-on-quarter (Q-o-Q) to Rs 122.3 crore in Q3FY25, from 179.1 crore in the September ...

At around 10:21 am, shares of Cyient were down 17.96% to Rs 1,438 on the Bombay Stock Exchange (BSE). In early trade, shares ...

Dr. Reddy's Laboratories shares fell by 6.2% after the company reported a marginal 2% YoY growth in Q3 FY25 net profit to Rs 1,413 crore. Despite robust revenue growth, Jefferies, Nuvama, and DAM ...

Nuvama slashed its FY25 and 26 EPS estimates by 10.8 per cent and 4.5 per cent, respectively, on lower growth and margins. It suggested a revised target price of Rs 1,660 from Rs 1,700 earlier.

Brokerages praise UltraTech Cement's Q3 performance, foreseeing market share gains and future growth despite profit decline ...